
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study
Shinji Ouma, Jiro Fukae, Shinsuke Fujioka, et al.
Internal Medicine (2017) Vol. 56, Iss. 15, pp. 1961-1966
Open Access | Times Cited: 21
Shinji Ouma, Jiro Fukae, Shinsuke Fujioka, et al.
Internal Medicine (2017) Vol. 56, Iss. 15, pp. 1961-1966
Open Access | Times Cited: 21
Showing 21 citing articles:
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
Nobutaka Hattori, Yoshio Tsuboi, Akihiko Yamamoto, et al.
Parkinsonism & Related Disorders (2020) Vol. 75, pp. 17-23
Open Access | Times Cited: 67
Nobutaka Hattori, Yoshio Tsuboi, Akihiko Yamamoto, et al.
Parkinsonism & Related Disorders (2020) Vol. 75, pp. 17-23
Open Access | Times Cited: 67
A Supervised Machine Learning Approach to Detect the On/Off State in Parkinson’s Disease Using Wearable Based Gait Signals
Satyabrata Aich, Jinyoung Youn, Sabyasachi Chakraborty, et al.
Diagnostics (2020) Vol. 10, Iss. 6, pp. 421-421
Open Access | Times Cited: 52
Satyabrata Aich, Jinyoung Youn, Sabyasachi Chakraborty, et al.
Diagnostics (2020) Vol. 10, Iss. 6, pp. 421-421
Open Access | Times Cited: 52
Characteristics of multimodal physiological signal differences in symptom fluctuations in Parkinson’s disease
Tian Zhang, Zhaohui Jin, K.S. Chen, et al.
Neuroscience (2025) Vol. 569, pp. 322-330
Closed Access
Tian Zhang, Zhaohui Jin, K.S. Chen, et al.
Neuroscience (2025) Vol. 569, pp. 322-330
Closed Access
Tolperisone hydrochloride improves motor functions in Parkinson’s disease via MMP-9 inhibition and by downregulating p38 MAPK and ERK1/2 signaling cascade
Bushra Zaman, Irona Mostafa, Tazree Hassan, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116438-116438
Open Access | Times Cited: 3
Bushra Zaman, Irona Mostafa, Tazree Hassan, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116438-116438
Open Access | Times Cited: 3
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study
Yoshio Tsuboi, Nobutaka Hattori, Akihiko Yamamoto, et al.
Journal of the Neurological Sciences (2020) Vol. 416, pp. 117012-117012
Open Access | Times Cited: 18
Yoshio Tsuboi, Nobutaka Hattori, Akihiko Yamamoto, et al.
Journal of the Neurological Sciences (2020) Vol. 416, pp. 117012-117012
Open Access | Times Cited: 18
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
К. Ray Chaudhuri, Per Odin, Joaquim J. Ferreira, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 10
К. Ray Chaudhuri, Per Odin, Joaquim J. Ferreira, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Profiling the most elderly parkinson’s disease patients: Does age or disease duration matter?
Sasivimol Virameteekul, Onanong Phokaewvarangkul, Roongroj Bhidayasiri
PLoS ONE (2021) Vol. 16, Iss. 12, pp. e0261302-e0261302
Open Access | Times Cited: 13
Sasivimol Virameteekul, Onanong Phokaewvarangkul, Roongroj Bhidayasiri
PLoS ONE (2021) Vol. 16, Iss. 12, pp. e0261302-e0261302
Open Access | Times Cited: 13
Development of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation
Veronica Di Battista, Evamarie Hey‐Hawkins
Journal of Pharmaceutical Sciences (2022) Vol. 111, Iss. 5, pp. 1262-1279
Closed Access | Times Cited: 8
Veronica Di Battista, Evamarie Hey‐Hawkins
Journal of Pharmaceutical Sciences (2022) Vol. 111, Iss. 5, pp. 1262-1279
Closed Access | Times Cited: 8
Wearing-off Identification in Parkinson's Disease: The shapd-woq Study
Ying Wan, Can-Xing Yuan, Xiaojun Hou, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 10
Ying Wan, Can-Xing Yuan, Xiaojun Hou, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 10
Analysis of Motor Complication and Relative Factors in a Cohort of Chinese Patients with Parkinson’s Disease
Baihua Sun, Tao Wang, Nianying Li, et al.
Parkinson s Disease (2020) Vol. 2020, pp. 1-7
Open Access | Times Cited: 10
Baihua Sun, Tao Wang, Nianying Li, et al.
Parkinson s Disease (2020) Vol. 2020, pp. 1-7
Open Access | Times Cited: 10
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials
Yoshio Tsuboi, Masatoshi Nakamura, Hidenori Maruyama, et al.
Journal of the Neurological Sciences (2021) Vol. 430, pp. 120026-120026
Open Access | Times Cited: 9
Yoshio Tsuboi, Masatoshi Nakamura, Hidenori Maruyama, et al.
Journal of the Neurological Sciences (2021) Vol. 430, pp. 120026-120026
Open Access | Times Cited: 9
Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease
Glenardi Glenardi, Tutwuri Handayani, Jimmy Barus, et al.
Neurology Clinical Practice (2021) Vol. 12, Iss. 2, pp. 139-148
Open Access | Times Cited: 8
Glenardi Glenardi, Tutwuri Handayani, Jimmy Barus, et al.
Neurology Clinical Practice (2021) Vol. 12, Iss. 2, pp. 139-148
Open Access | Times Cited: 8
Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
Masahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 2, pp. 180-189
Open Access | Times Cited: 6
Masahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 2, pp. 180-189
Open Access | Times Cited: 6
Real-world assessment of “OFF” episode–related healthcare resource utilization among patients with Parkinson’s disease in the United States
Andrew Thach, Eddie Jones, Eric J. Pappert, et al.
Journal of Medical Economics (2021) Vol. 24, Iss. 1, pp. 540-549
Open Access | Times Cited: 5
Andrew Thach, Eddie Jones, Eric J. Pappert, et al.
Journal of Medical Economics (2021) Vol. 24, Iss. 1, pp. 540-549
Open Access | Times Cited: 5
The Risk Factors for the Wearing-Off Phenomenon in Parkinson's Disease
Kunal Raja, Sonam Ramrakhia, Kapeel Dev, et al.
Cureus (2020)
Open Access | Times Cited: 4
Kunal Raja, Sonam Ramrakhia, Kapeel Dev, et al.
Cureus (2020)
Open Access | Times Cited: 4
Off Time Independently Affects Quality of Life in Advanced Parkinson’s Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson’s Disease (JAQPAD) Study
Yuka Hayashi, Ryoko Nakagawa, Miwako Ishido, et al.
Parkinson s Disease (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 4
Yuka Hayashi, Ryoko Nakagawa, Miwako Ishido, et al.
Parkinson s Disease (2021) Vol. 2021, pp. 1-9
Open Access | Times Cited: 4
Real-World Experiences of Parkinson's Disease OFF Time and Role of Demographics
Radhika Devraj, Ahmad Elkouzi, Marlon R. Tracey
Journal of patient-centered research and reviews (2024) Vol. 11, Iss. 1, pp. 8-17
Open Access
Radhika Devraj, Ahmad Elkouzi, Marlon R. Tracey
Journal of patient-centered research and reviews (2024) Vol. 11, Iss. 1, pp. 8-17
Open Access
Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease
Nayoung Kwak, Myung‐Jun Lee, Hye‐Young Kang, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 9, pp. 670-676
Closed Access
Nayoung Kwak, Myung‐Jun Lee, Hye‐Young Kang, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 9, pp. 670-676
Closed Access
Validating the Vietnamese version of wearing – Off 19 questionnaire for patients with Parkinson's disease
Uyen Le Ngoc Ha, Tai Ngoc Tran, Văn Minh Lê, et al.
Clinical Parkinsonism & Related Disorders (2019) Vol. 1, pp. 37-40
Open Access | Times Cited: 2
Uyen Le Ngoc Ha, Tai Ngoc Tran, Văn Minh Lê, et al.
Clinical Parkinsonism & Related Disorders (2019) Vol. 1, pp. 37-40
Open Access | Times Cited: 2
How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists
Yuki Yasutaka, Shinsuke Fujioka, Takayasu Mishima, et al.
Clinical Neurology and Neurosurgery (2020) Vol. 199, pp. 106266-106266
Closed Access | Times Cited: 2
Yuki Yasutaka, Shinsuke Fujioka, Takayasu Mishima, et al.
Clinical Neurology and Neurosurgery (2020) Vol. 199, pp. 106266-106266
Closed Access | Times Cited: 2
Association of Depression With Early Occurrence of Postural Instability in Parkinson’s Disease
Yun Su Hwang, Sungyang Jo, Kye Won Park, et al.
Journal of Movement Disorders (2022) Vol. 16, Iss. 1, pp. 68-78
Open Access | Times Cited: 1
Yun Su Hwang, Sungyang Jo, Kye Won Park, et al.
Journal of Movement Disorders (2022) Vol. 16, Iss. 1, pp. 68-78
Open Access | Times Cited: 1